Taro Wants the States’ Consumer Claims Thrown Out as Duplicates of Its $200 Million Generic Drug Deal — and the Claim Deadline for That Deal Stays November 9, 2026

The short answer for anyone who paid for generic prescriptions between 2009 and 2019: nothing about your claim has changed, and the date that matters is November 9, 2026. The court-authorized notice puts it plainly: “If you do not submit your claim form on or before November 9, 2026, you will not get a payment from the settlements.” The Taro generic drug antitrust settlement — formally the end-payer settlement with Sun Pharmaceutical Industries, Inc. and Taro Pharmaceuticals U.S.A., Inc. — is worth $200 million and received final approval from Judge Cynthia M. Rufe of the Eastern District of Pennsylvania in an order of January 23, 2026, according to Bloomberg Law.

What is new since our claim-form guide of September 30 is happening around that deal, not inside it. On September 11, 2026, Sun Pharmaceutical Industries Ltd. told Indian stock exchanges that three subsidiaries — Sun Pharmaceutical Industries, Inc., Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A. — had signed a settlement agreement “with a plaintiff” in the same multidistrict litigation “for a confidential amount,” in Bloomberg Law’s words. And on October 9, 2026, Law360 reported that Taro Pharmaceuticals USA had asked a Connecticut federal judge to toss price-fixing claims that a coalition of states brought on behalf of consumers, arguing they are duplicative of claims the consumers have already pursued — Law360 lists the motion together with the “Taro EPP Settlement,” the $200 million class deal, as its source documents. Neither event creates a new claim form, changes the deadline or changes what a consumer has to send.

The money sits in four end-payer settlements that share one claim process. The notice lists them: “Sandoz paid $275 million and Sun/Taro paid $200 million to settle all consumer and TPP claims in this lawsuit. Heritage paid $10 million and Apotex paid $48 million to settle the TPP claims in this lawsuit.” TPPs are third-party payers — insurers and employers or unions with self-funded drug plans. That makes $533 million in all, but only the Sandoz and Sun/Taro money is open to individual consumers.

You are in the class if you “indirectly purchased, paid for, and/or provided reimbursement for some or all of the purchase price for one or more of the Named Generic Drugs, either for personal use by yourself or your members, and other than for resale, in the United States (except Indiana and Ohio) and in some United States territories, at any time during the period from May 1, 2009, through December 31, 2019.” “Indirectly” means you bought at a pharmacy or by mail order, not from the manufacturer. “Some or all” means a copay counts. The drug list matters: only the Named Generic Drugs, in the listed forms and strengths, qualify, and the site has a lookup tool.

How much: no one knows yet. Payment is pro rata — the notice says your amount “will depend on the number of valid claims and the amount of money you spent on the Named Generic Drugs from May 1, 2009 through December 31, 2019.” Notice and administration costs, attorneys’ fees, litigation expenses, future litigation expenses and service awards come off first. As of October 18, 2026, no per-person estimate and no payment date have been published that we could find; Top Class Actions, reporting on October 5, 2026, also found that “No specific payment estimate is available at this time.” Payments will not follow right after the deadline: claims have to be reviewed, deficient ones given a chance to be fixed, and the court has to approve the distribution first.

File one claim form with proof. The notice requires “a claim form with supporting documents” — in practice a receipt, an account statement or a pharmacy printout showing that you bought each drug you list at least once in the period. Pharmacy records going back to 2009 can take time to get, so ask your pharmacy now. You can file online at GenericDrugsEndPayerSettlement.com by November 9, 2026, or mail a paper form “postmarked on or before November 9, 2026.” A paper copy can be downloaded from the site or mailed to you if you call 1-877-316-0171.

One practical snag: when we opened the official site on October 18, 2026, it answered with this message instead of the online form: “Online filing is not available for your connection due to site security measures. The settlement website is operating normally, and a claim form is available there to download, complete, and submit by mail.” If you see the same screen, try another network, or download the paper form and mail it with a postmark by November 9, 2026. Paper filers should keep a copy and use a mailing method with proof of mailing.

Two groups should not wait for this deadline at all. Wholesalers and other direct purchasers had a separate Sun/Taro settlement worth $85,000,000 — $17,357,000 from Sun and its affiliates and $67,643,000 from Taro — whose claim forms were due May 6, 2024; that site states that “If you purchased these drugs from a retail pharmacy (e.g., Walgreens, CVS, Walmart, Rite Aid etc.), you are not a Settlement Class Member.” And the earlier deadlines in the end-payer case have passed: the deadline to opt out or object to the Sun/Taro deal was December 2, 2025, before the final approval hearing of January 15, 2026.

A postcard, email or ad that sends you to GenericDrugsEndPayerSettlement.com and lists 1-877-316-0171 matches the court-authorized notice, which says: “A federal court authorized this Notice. This is not a solicitation from a lawyer.” Type the address yourself rather than clicking a link in a message you did not expect. Filing is free.

Be wary of anyone who offers to file for a share of your payment. The notice is explicit: “Settlement Class Members do not need to sign up with a claims recovery firm or pay another law firm in order to participate in these settlements.” The administrator answers questions at the toll-free number and through the “Contact Us” page of the official site. The September 11 confidential deal is not a reason for anyone to contact you: it was signed with one plaintiff, its amount and other terms are confidential, and, according to the company, it was made “without any admission of wrongdoing.” A message claiming to pay you from that deal is not backed by anything public.

The generic-drug case runs on two tracks. In Philadelphia, MDL No. 2724 gathers the class actions by direct and indirect purchasers; the court’s MDL page notes that the panel also “expanded the scope of the MDL to include claims brought by 40 States, proceeding through their Attorneys General.” The states’ own lawsuits against the manufacturers are being litigated in the federal court in Connecticut, among them Connecticut v. Teva (No. 3:19-cv-00710) and Connecticut v. Sandoz (No. 3:20-cv-00802). Part of what the states seek is money for residents who overpaid.

Taro’s argument, as Law360 summarized it in its opening line, is that the states’ claims on behalf of consumers duplicate claims the consumers have already pursued; Law360 lists the Taro EPP Settlement among the motion’s documents. That is Taro’s position in a motion, not a ruling; we could not read the motion itself or find a court decision on it as of October 18, 2026. If the judge agrees, consumers who want money from Taro for these drugs would have one route left — the class claim with the November 9 deadline. If the judge disagrees, the state case continues against Taro. Either way, filing a class claim now costs nothing and does not depend on the outcome. The states’ separate claim program for other defendants is covered in our report on the Ascend and Mayne deals.

Our docket database shows entries titled “Order on Motion for Settlement” on October 16, 2026 in three of the states’ Connecticut cases. In Connecticut v. Sandoz (No. 3:20-cv-00802) that order was the preliminary approval of the states’ $400 million Sandoz and Fougera settlement, as Law360 reported; the entries in the other two cases carry no text, so we do not know what they decided and do not treat them as news about Taro.

Who bought Taro Pharmaceuticals? Sun Pharmaceutical Industries Ltd., which already controlled it, bought out the remaining shareholders. Taro’s SEC filing on the closing states: “The Merger became effective on June 24, 2024 … As a result of the Merger, the Company became a private company and an indirect wholly-owned subsidiary of Sun Pharma.” Public shareholders received $43.00 a share in cash, and the shares stopped trading on the New York Stock Exchange.

Is Taro Pharmaceuticals still in business? Yes, as a Sun subsidiary. Both Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A. are named as parties to the confidential settlement Sun disclosed in September 2026. That matters for claimants only in one way: the $200 million was paid by the settling companies into the class fund, and the claim runs against that fund, not against Taro’s business.

This is not Taro’s first payment over generic-drug pricing. According to its 2023 annual report, Taro U.S.A. entered a deferred prosecution agreement with the Justice Department’s Antitrust Division on July 23, 2020 over “conduct allegedly occurring between 2013 and 2015” and paid a penalty of $205.7 million; on September 30, 2021 it agreed to pay $213.3 million to resolve federal health-care program claims. Its direct-purchaser settlement of $67.6 million was approved in March 2023 and reduced by $7.96 million because of opt-outs. None of that money goes to consumers through this claim form.

One more thing the search results mix up: Taro’s shareholder litigation. Speakes v. Taro Pharmaceutical Industries, Ltd., filed October 25, 2016 in the Southern District of New York, is a securities case brought on behalf of investors, not a drug-price case. The generic drug settlement does not cover stock losses, and buying a generic prescription does not make you a member of that case; investors have to look to that case’s own notice and administrator.